You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameZuclopenthixol
Accession NumberDB01624  (DB08919, DB08920)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionZuclopenthixol, also known as Zuclopentixol or Zuclopenthixolum, is an antipsychotic agent. Zuclopenthixol is a thioxanthene-based neuroleptic with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors. Major brands of zuclopenthixol are Cisordinol, Acuphase, and Clopixol. This drug is a liquid. This compound belongs to the thioxanthenes. These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom. Known drug targets of zuclopenthixol include 5-hydroxytryptamine receptor 2A, D(1B) dopamine receptor, D(2) dopamine receptor, D(1A) dopamine receptor, and alpha-1A adrenergic receptor. It is known that zuclopenthixol is metabolized by Cytochrome P450 2D6. Zuclopenthixol was approved for use in Canada in 2011, but is not approved for use in the United States.
Structure
Thumb
Synonyms
cis-Clopenthixol
Zuclopenthixolum
Zuclopentixol
External Identifiers
  • N05AF05
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Clopixol - Tab 10mgtablet10 mgoralHoechst Marion Roussel Canada Inc.1995-12-311999-08-11Canada
Clopixol - Tab 25mgtablet25 mgoralHoechst Marion Roussel Canada Inc.1995-12-311999-08-11Canada
Clopixol - Tab 40mgtablet40 mgoralHoechst Marion Roussel Canada Inc.1995-12-311999-08-11Canada
Clopixol Acuphase - Liq Im 50mg/mlliquid50 mgintramuscularHoechst Marion Roussel Canada Inc.1995-12-311999-08-11Canada
Clopixol Depot - Liq Im 200mg/mlliquid200 mgintramuscularHoechst Marion Roussel Canada Inc.1995-12-311999-08-11Canada
Clopixol Depot - Liq Im 500mg/mlliquid500 mgintramuscularHoechst Marion Roussel Canada Inc.1995-12-311999-08-11Canada
Clopixol Depot 200mg/mlsolution200 mgintramuscularLundbeck Canada Inc1997-05-02Not applicableCanada
Clopixol Depot 500mg/mlliquid500 mgintramuscularLundbeck Canada IncNot applicableNot applicableCanada
Clopixol Tablets 10mgtablet10 mgoralLundbeck Canada Inc1997-05-02Not applicableCanada
Clopixol Tablets 25mgtablet25 mgoralLundbeck Canada Inc1997-05-02Not applicableCanada
Clopixol Tablets 40mgtablet40 mgoralLundbeck Canada Inc1997-05-022003-03-24Canada
Clopixol-acuphase 50mg/mlsolution50 mgintramuscularLundbeck Canada Inc1997-05-02Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AcuphaseH. Lundbeck A/S
Ciatyl-ZBayer Vital
CisordinolH. Lundbeck A/S
ClopixolH. Lundbeck A/S
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Zuclopenthixol acetate
Thumb
  • InChI Key: OXAUOBQMCDIVPQ-IOXNKQMXSA-N
  • Monoisotopic Mass: 442.148176515
  • Average Mass: 443.001
DBSALT000545
Zuclopenthixol decanoate
64053-00-5
Thumb
  • InChI Key: QRUAPADZILXULG-WKIKZPBSSA-N
  • Monoisotopic Mass: 554.273377027
  • Average Mass: 555.214
DBSALT000787
Zuclopenthixol dihydrochloride
Thumb
  • InChI Key: LPWNZMIBFHMYMX-MHKBYHAFSA-N
  • Monoisotopic Mass: 472.090967307
  • Average Mass: 473.887
DBSALT000546
Categories
UNII47ISU063SG
CAS number53772-83-1
WeightAverage: 400.965
Monoisotopic: 400.137611829
Chemical FormulaC22H25ClN2OS
InChI KeyInChIKey=WFPIAZLQTJBIFN-DVZOWYKESA-N
InChI
InChI=1S/C22H25ClN2OS/c23-17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)27-22)5-3-9-24-10-12-25(13-11-24)14-15-26/h1-2,4-8,16,26H,3,9-15H2/b18-5-
IUPAC Name
2-(4-{3-[(9Z)-2-chloro-9H-thioxanthen-9-ylidene]propyl}piperazin-1-yl)ethan-1-ol
SMILES
OCCN1CCN(CC\C=C2\C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as thioxanthenes. These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiopyrans
Sub Class1-benzothiopyrans
Direct ParentThioxanthenes
Alternative Parents
Substituents
  • Thioxanthene
  • Diarylthioether
  • N-alkylpiperazine
  • Chlorobenzene
  • Benzenoid
  • Piperazine
  • 1,4-diazinane
  • Aryl halide
  • Aryl chloride
  • Tertiary aliphatic amine
  • Tertiary amine
  • 1,2-aminoalcohol
  • Azacycle
  • Thioether
  • Alkanolamine
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationUsed in the management of acute psychoses such as mania or schizophrenia. However, the use of zuclopenthixol acetate in psychiatric emergencies as an alternative to standard treatments (haloperidol, clotiapine, etc.) should be cautioned, since well executed and documented trials of zuclopenthixol acetate for this use have yet to be conducted. Zuclopenthixol acetate is not intended for long-term use.
PharmacodynamicsZuclopenthixol is a thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors.
Mechanism of actionZuclopenthixol is a typical antipsychotic neuroleptic drug of the thioxanthene class. It mainly acts by antagonism of D1 and D2 dopamine receptors. Zuclopenthixol also has high affinity for alpha1-adrenergic and 5-HT2 receptors. It has weaker histamine H1 receptor blocking activity, and even lower affinity for muscarinic cholinergic and alpha2-adrenergic receptors.
Related Articles
AbsorptionUpon reaching the body water phase, the decanoate ester is slowly released from the oil depot, which is resultantly hydrolyzed to the active substance, zuclopenthixol. The decanoate ester provides a means of slow release since zuclopenthixol itself is a short-acting drug.
Volume of distribution

20 L/kg.

Protein binding98-99%
Metabolism

The metabolism of zuclopenthixol is mainly by sulphoxidation, side chain N-dealkylation and glucuronic acid conjugation. The metabolites are devoid of pharmacological activity.

Route of eliminationPrimarily in the feces with approximately 10% in the urine.
Half life20 hours (range 12-28 hours) for the tablet form, 19 days for the depot form.
Clearance

approximately 0.9 L/min.

ToxicityAlthough there have not been any cases of overdosage reported, the symptoms are likely to be somnolence, coma, extrapyramidal symptoms, convulsions, hypotension, shock, or hyper- or hypothermia. Neuroleptic malignant syndrome may occur. Zuclopenthixol may potentiate anticholinergic effects of concurrent medications. Zuclopenthixol has a demonstrated antiemetic effect in animals, and may mask signs of toxicity due to other drug overdoses, or may mask symptoms of disease.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9443
Blood Brain Barrier+0.9676
Caco-2 permeable-0.5313
P-glycoprotein substrateSubstrate0.8762
P-glycoprotein inhibitor IInhibitor0.8736
P-glycoprotein inhibitor IIInhibitor0.7439
Renal organic cation transporterInhibitor0.5829
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6722
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorInhibitor0.7518
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8213
Ames testNon AMES toxic0.7617
CarcinogenicityNon-carcinogens0.9029
BiodegradationNot ready biodegradable0.9954
Rat acute toxicity2.8877 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6099
hERG inhibition (predictor II)Inhibitor0.7023
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral40 mg
Liquidintramuscular50 mg
Liquidintramuscular200 mg
Liquidintramuscular500 mg
Solutionintramuscular200 mg
Tabletoral10 mg
Tabletoral25 mg
Solutionintramuscular50 mg
Prices
Unit descriptionCostUnit
Clopixol Acuphase 50 mg/ml16.52USD ml
Clopixol Depot 200 mg/ml16.52USD ml
Clopixol 25 mg Tablet1.06USD tablet
Clopixol 10 mg Tablet0.42USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point~50http://www.lundbeck.com/upload/ca/en/files/pdf/product_monograph/Clopixol_PM_MKT_ctrl_148975_13SEPT2011_CLN_eng.pdf
water solubilityslighthttp://www.lundbeck.com/upload/ca/en/files/pdf/product_monograph/Clopixol_PM_MKT_ctrl_148975_13SEPT2011_CLN_eng.pdf
Predicted Properties
PropertyValueSource
Water Solubility0.0026 mg/mLALOGPS
logP4.46ALOGPS
logP4.22ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)15.59ChemAxon
pKa (Strongest Basic)8.43ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area26.71 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity127 m3·mol-1ChemAxon
Polarizability45.29 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (140 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Khalifa AE: Zuclopenthixol facilitates memory retrieval in rats: possible involvement of noradrenergic and serotonergic mechanisms. Pharmacol Biochem Behav. 2003 Jul;75(4):755-62. [PubMed:12957216 ]
  2. Fond G, Macgregor A, Tamouza R, Hamdani N, Meary A, Leboyer M, Dubremetz JF: Comparative analysis of anti-toxoplasmic activity of antipsychotic drugs and valproate. Eur Arch Psychiatry Clin Neurosci. 2014 Mar;264(2):179-83. doi: 10.1007/s00406-013-0413-4. Epub 2013 Jun 15. [PubMed:23771405 ]
  3. Jayakody K, Gibson RC, Kumar A, Gunadasa S: Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Cochrane Database Syst Rev. 2012 Apr 18;4:CD000525. doi: 10.1002/14651858.CD000525.pub3. [PubMed:22513898 ]
  4. Nielsen MK, Johansen SS: Simultaneous determination of 25 common pharmaceuticals in whole blood using ultra-performance liquid chromatography-tandem mass spectrometry. J Anal Toxicol. 2012 Sep;36(7):497-506. doi: 10.1093/jat/bks054. Epub 2012 Jun 19. [PubMed:22718540 ]
  5. Khalifa AE: Pro-oxidant activity of zuclopenthixol in vivo: differential effect of the drug on brain oxidative status of scopolamine-treated rats. Hum Exp Toxicol. 2004 Aug;23(9):439-45. [PubMed:15497819 ]
  6. Hood S, Orr K, Bennett L, Davies S: Severe laryngeal dystonia in a patient receiving zuclopenthixol "Acuphase" and fluoxetine. Australas Psychiatry. 2010 Apr;18(2):174-6. doi: 10.3109/10398560903473686. [PubMed:20175668 ]
  7. Link [Link]
  8. Link [Link]
External Links
ATC CodesN05AF05
AHFS Codes
  • 281608
PDB EntriesNot Available
FDA labelDownload (229 KB)
MSDSDownload (568 KB)
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineZuclopenthixol may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineZuclopenthixol may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with 7-Nitroindazole.
AbirateroneThe metabolism of Zuclopenthixol can be decreased when combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Zuclopenthixol.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Zuclopenthixol.
adipiplonThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Zuclopenthixol.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Zuclopenthixol.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Zuclopenthixol.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Zuclopenthixol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Zuclopenthixol.
AmantadineAmantadine may increase the QTc-prolonging activities of Zuclopenthixol.
AmiodaroneAmiodarone may increase the QTc-prolonging activities of Zuclopenthixol.
AmisulprideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Zuclopenthixol.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Zuclopenthixol.
AmoxapineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Amperozide.
AmphetamineZuclopenthixol may decrease the stimulatory activities of Amphetamine.
AnagrelideAnagrelide may increase the QTc-prolonging activities of Zuclopenthixol.
ApomorphineApomorphine may increase the QTc-prolonging activities of Zuclopenthixol.
AprepitantThe serum concentration of Zuclopenthixol can be increased when it is combined with Aprepitant.
ArformoterolArformoterol may increase the QTc-prolonging activities of Zuclopenthixol.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Zuclopenthixol.
Arsenic trioxideArsenic trioxide may increase the QTc-prolonging activities of Zuclopenthixol.
ArtemetherZuclopenthixol may increase the QTc-prolonging activities of Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Articaine.
AsenapineZuclopenthixol may increase the QTc-prolonging activities of Asenapine.
AtazanavirThe serum concentration of Zuclopenthixol can be increased when it is combined with Atazanavir.
AtomoxetineThe serum concentration of Zuclopenthixol can be increased when it is combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Azaperone.
AzelastineZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Zuclopenthixol.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Zuclopenthixol.
BaclofenThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Zuclopenthixol.
BedaquilineBedaquiline may increase the QTc-prolonging activities of Zuclopenthixol.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Zuclopenthixol.
BenzphetamineZuclopenthixol may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Benzyl alcohol.
BetaxololThe metabolism of Zuclopenthixol can be decreased when combined with Betaxolol.
BoceprevirThe serum concentration of Zuclopenthixol can be increased when it is combined with Boceprevir.
BortezomibThe serum concentration of Zuclopenthixol can be increased when it is combined with Bortezomib.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.
BrimonidineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Zuclopenthixol.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Zuclopenthixol.
BrompheniramineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Zuclopenthixol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Zuclopenthixol.
BupropionThe metabolism of Zuclopenthixol can be decreased when combined with Bupropion.
BuserelinBuserelin may increase the QTc-prolonging activities of Zuclopenthixol.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Zuclopenthixol.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Zuclopenthixol.
ButacaineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Zuclopenthixol.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Zuclopenthixol.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Zuclopenthixol.
CarbamazepineThe serum concentration of Zuclopenthixol can be decreased when it is combined with Carbamazepine.
CarbamazepineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Zuclopenthixol.
CarisoprodolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Carisoprodol.
CelecoxibThe metabolism of Zuclopenthixol can be decreased when combined with Celecoxib.
CeritinibCeritinib may increase the QTc-prolonging activities of Zuclopenthixol.
CetirizineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Zuclopenthixol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Zuclopenthixol.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Zuclopenthixol.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Zuclopenthixol.
ChloroquineChloroquine may increase the QTc-prolonging activities of Zuclopenthixol.
ChlorphenamineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Chlorphenamine.
ChlorphentermineZuclopenthixol may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Zuclopenthixol.
ChlorpromazineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Zuclopenthixol.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Zuclopenthixol can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Zuclopenthixol can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Zuclopenthixol can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Zuclopenthixol.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Zuclopenthixol.
CisaprideCisapride may increase the QTc-prolonging activities of Zuclopenthixol.
CitalopramCitalopram may increase the QTc-prolonging activities of Zuclopenthixol.
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Zuclopenthixol.
ClemastineThe serum concentration of Zuclopenthixol can be increased when it is combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Clidinium.
ClobazamThe metabolism of Zuclopenthixol can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zuclopenthixol.
ClotrimazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Clotrimazole.
ClozapineClozapine may increase the QTc-prolonging activities of Zuclopenthixol.
ClozapineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Clozapine.
CobicistatThe serum concentration of Zuclopenthixol can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Zuclopenthixol.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Zuclopenthixol.
ConivaptanThe serum concentration of Zuclopenthixol can be increased when it is combined with Conivaptan.
CrizotinibCrizotinib may increase the QTc-prolonging activities of Zuclopenthixol.
CyclizineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zuclopenthixol.
CyclosporineThe serum concentration of Zuclopenthixol can be increased when it is combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Cyproheptadine.
DabrafenibDabrafenib may increase the QTc-prolonging activities of Zuclopenthixol.
DantroleneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zuclopenthixol.
DapoxetineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dapoxetine.
DarifenacinThe metabolism of Zuclopenthixol can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Zuclopenthixol can be increased when it is combined with Darunavir.
DasatinibDasatinib may increase the QTc-prolonging activities of Zuclopenthixol.
DegarelixDegarelix may increase the QTc-prolonging activities of Zuclopenthixol.
DelavirdineThe serum concentration of Zuclopenthixol can be increased when it is combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Zuclopenthixol.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Zuclopenthixol.
DesloratadineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Zuclopenthixol.
DetomidineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Zuclopenthixol.
DextroamphetamineZuclopenthixol may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Zuclopenthixol.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Zuclopenthixol.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Zuclopenthixol.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Zuclopenthixol.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Zuclopenthixol.
DifenoxinThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Zuclopenthixol.
DihydroergotamineThe serum concentration of Zuclopenthixol can be increased when it is combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Zuclopenthixol.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Zuclopenthixol.
DiltiazemThe serum concentration of Zuclopenthixol can be increased when it is combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Zuclopenthixol can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Zuclopenthixol.
DisopyramideDisopyramide may increase the QTc-prolonging activities of Zuclopenthixol.
DofetilideDofetilide may increase the QTc-prolonging activities of Zuclopenthixol.
DolasetronDolasetron may increase the QTc-prolonging activities of Zuclopenthixol.
DomperidoneDomperidone may increase the QTc-prolonging activities of Zuclopenthixol.
DoramectinThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Zuclopenthixol.
DoxycyclineThe serum concentration of Zuclopenthixol can be increased when it is combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.
DoxylamineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.
DronedaroneZuclopenthixol may increase the QTc-prolonging activities of Dronedarone.
DroperidolDroperidol may increase the QTc-prolonging activities of Zuclopenthixol.
DroperidolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Zuclopenthixol.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Zuclopenthixol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Zuclopenthixol.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Zuclopenthixol.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Zuclopenthixol.
EliglustatZuclopenthixol may increase the QTc-prolonging activities of Eliglustat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Zuclopenthixol.
EntacaponeThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Entacapone.
EnzalutamideThe serum concentration of Zuclopenthixol can be decreased when it is combined with Enzalutamide.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Zuclopenthixol.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Zuclopenthixol.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Zuclopenthixol.
EribulinEribulin may increase the QTc-prolonging activities of Zuclopenthixol.
ErythromycinErythromycin may increase the QTc-prolonging activities of Zuclopenthixol.
EscitalopramEscitalopram may increase the QTc-prolonging activities of Zuclopenthixol.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Zuclopenthixol.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Zuclopenthixol.
EthanolZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Zuclopenthixol.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zuclopenthixol.
EthosuximideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Zuclopenthixol.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Zuclopenthixol.
EtidocaineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Zuclopenthixol.
EtoperidoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Zuclopenthixol.
EzogabineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ezogabine.
FamotidineFamotidine may increase the QTc-prolonging activities of Zuclopenthixol.
FelbamateThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Zuclopenthixol.
FenfluramineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Zuclopenthixol.
FexofenadineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fexofenadine.
FingolimodFingolimod may increase the QTc-prolonging activities of Zuclopenthixol.
FlecainideFlecainide may increase the QTc-prolonging activities of Zuclopenthixol.
FlibanserinThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Flibanserin.
FluconazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Zuclopenthixol.
FlunarizineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Zuclopenthixol.
FluoxetineFluoxetine may increase the QTc-prolonging activities of Zuclopenthixol.
FlupentixolFlupentixol may increase the QTc-prolonging activities of Zuclopenthixol.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Zuclopenthixol.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Zuclopenthixol.
FluspirileneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fluticasone Propionate.
FluvoxamineThe serum concentration of Zuclopenthixol can be increased when it is combined with Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Zuclopenthixol.
FosamprenavirThe serum concentration of Zuclopenthixol can be increased when it is combined with Fosamprenavir.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Zuclopenthixol.
FosphenytoinThe serum concentration of Zuclopenthixol can be decreased when it is combined with Fosphenytoin.
FosphenytoinThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Zuclopenthixol.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Zuclopenthixol.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with gabapentin enacarbil.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Zuclopenthixol.
GalantamineGalantamine may increase the QTc-prolonging activities of Zuclopenthixol.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Zuclopenthixol.
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Zuclopenthixol.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Zuclopenthixol.
GoserelinGoserelin may increase the QTc-prolonging activities of Zuclopenthixol.
GranisetronGranisetron may increase the QTc-prolonging activities of Zuclopenthixol.
GuanfacineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Zuclopenthixol.
HaloperidolHaloperidol may increase the QTc-prolonging activities of Zuclopenthixol.
HaloperidolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Zuclopenthixol.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Zuclopenthixol.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Zuclopenthixol.
HistrelinHistrelin may increase the QTc-prolonging activities of Zuclopenthixol.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Zuclopenthixol.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Zuclopenthixol.
Hydroxyamphetamine hydrobromideZuclopenthixol may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.
HydroxyzineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Hydroxyzine.
IbandronateIbandronate may increase the QTc-prolonging activities of Zuclopenthixol.
IbutilideIbutilide may increase the QTc-prolonging activities of Zuclopenthixol.
IdelalisibThe serum concentration of Zuclopenthixol can be increased when it is combined with Idelalisib.
IloperidoneZuclopenthixol may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe serum concentration of Zuclopenthixol can be increased when it is combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Zuclopenthixol.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Zuclopenthixol.
IndalpineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Indalpine.
IndapamideIndapamide may increase the QTc-prolonging activities of Zuclopenthixol.
IndinavirThe metabolism of Zuclopenthixol can be decreased when combined with Indinavir.
IsavuconazoniumThe serum concentration of Zuclopenthixol can be increased when it is combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Zuclopenthixol.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Zuclopenthixol.
IsoniazidThe metabolism of Zuclopenthixol can be decreased when combined with Isoniazid.
IsradipineThe serum concentration of Zuclopenthixol can be increased when it is combined with Isradipine.
ItraconazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Itraconazole.
IvabradineIvabradine may increase the QTc-prolonging activities of Zuclopenthixol.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Zuclopenthixol.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Zuclopenthixol.
KetobemidoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ketobemidone.
KetoconazoleThe metabolism of Zuclopenthixol can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lamotrigine.
LapatinibLapatinib may increase the QTc-prolonging activities of Zuclopenthixol.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Zuclopenthixol.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Zuclopenthixol.
LevetiracetamThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Zuclopenthixol.
LevocabastineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Levodopa.
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Zuclopenthixol.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Zuclopenthixol.
LevomilnacipranThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Zuclopenthixol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Zuclopenthixol.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Zuclopenthixol.
LisdexamfetamineZuclopenthixol may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Zuclopenthixol.
LithiumThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lofentanil.
LopinavirLopinavir may increase the QTc-prolonging activities of Zuclopenthixol.
LoratadineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Zuclopenthixol.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Zuclopenthixol.
LovastatinThe serum concentration of Zuclopenthixol can be increased when it is combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Zuclopenthixol.
Lu AA21004The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lu AA21004.
LuliconazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Luliconazole.
LumefantrineZuclopenthixol may increase the QTc-prolonging activities of Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Zuclopenthixol.
MeclizineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Medetomidine.
MefloquineMefloquine may increase the QTc-prolonging activities of Zuclopenthixol.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Zuclopenthixol.
MelperoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Melperone.
MephentermineZuclopenthixol may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Zuclopenthixol.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zuclopenthixol.
MequitazineZuclopenthixol may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Zuclopenthixol.
MetaxaloneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Metaxalone.
MethadoneMethadone may increase the QTc-prolonging activities of Zuclopenthixol.
MethadoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Zuclopenthixol.
MethamphetamineZuclopenthixol may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Zuclopenthixol.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Zuclopenthixol.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Zuclopenthixol.
MethsuximideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Zuclopenthixol.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Zuclopenthixol.
MetoprololThe metabolism of Zuclopenthixol can be decreased when combined with Metoprolol.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Zuclopenthixol.
MetyrosineZuclopenthixol may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Zuclopenthixol.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Zuclopenthixol.
MifepristoneMifepristone may increase the QTc-prolonging activities of Zuclopenthixol.
MilnacipranThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.
MirabegronThe metabolism of Zuclopenthixol can be decreased when combined with Mirabegron.
MirtazapineZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Zuclopenthixol.
MitotaneThe serum concentration of Zuclopenthixol can be decreased when it is combined with Mitotane.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Zuclopenthixol.
MoexiprilMoexipril may increase the QTc-prolonging activities of Zuclopenthixol.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Zuclopenthixol.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Zuclopenthixol.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Zuclopenthixol.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.
NabiloneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Zuclopenthixol.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Zuclopenthixol.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Zuclopenthixol.
NelfinavirThe serum concentration of Zuclopenthixol can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Zuclopenthixol can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Zuclopenthixol can be decreased when it is combined with Nevirapine.
NicardipineThe metabolism of Zuclopenthixol can be decreased when combined with Nicardipine.
NilotinibZuclopenthixol may increase the QTc-prolonging activities of Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Zuclopenthixol.
Nitrous oxideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Nitrous oxide.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Zuclopenthixol.
NormethadoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Zuclopenthixol.
OctreotideOctreotide may increase the QTc-prolonging activities of Zuclopenthixol.
OfloxacinOfloxacin may increase the QTc-prolonging activities of Zuclopenthixol.
OlanzapineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Olanzapine.
OlaparibThe serum concentration of Zuclopenthixol can be increased when it is combined with Olaparib.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Zuclopenthixol.
OlopatadineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Olopatadine.
OndansetronOndansetron may increase the QTc-prolonging activities of Zuclopenthixol.
OndansetronThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Opium.
OrphenadrineZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Zuclopenthixol.
OsanetantThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Zuclopenthixol.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Zuclopenthixol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Zuclopenthixol.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Zuclopenthixol.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Zuclopenthixol.
OxytocinOxytocin may increase the QTc-prolonging activities of Zuclopenthixol.
PaliperidonePaliperidone may increase the QTc-prolonging activities of Zuclopenthixol.
PanobinostatPanobinostat may increase the QTc-prolonging activities of Zuclopenthixol.
ParaldehydeZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Zuclopenthixol.
ParoxetineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Paroxetine.
PasireotidePasireotide may increase the QTc-prolonging activities of Zuclopenthixol.
PazopanibPazopanib may increase the QTc-prolonging activities of Zuclopenthixol.
Peginterferon alfa-2bThe serum concentration of Zuclopenthixol can be decreased when it is combined with Peginterferon alfa-2b.
PentamidinePentamidine may increase the QTc-prolonging activities of Zuclopenthixol.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Zuclopenthixol.
PentobarbitalThe serum concentration of Zuclopenthixol can be decreased when it is combined with Pentobarbital.
PentobarbitalThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pentobarbital.
PerampanelThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Perampanel.
PerflutrenPerflutren may increase the QTc-prolonging activities of Zuclopenthixol.
PerospironeThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Zuclopenthixol.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Zuclopenthixol.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Zuclopenthixol.
PhenobarbitalThe serum concentration of Zuclopenthixol can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Phenoxyethanol.
PhentermineZuclopenthixol may decrease the stimulatory activities of Phentermine.
PhenytoinThe serum concentration of Zuclopenthixol can be decreased when it is combined with Phenytoin.
PhenytoinThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Phenytoin.
PimozidePimozide may increase the QTc-prolonging activities of Zuclopenthixol.
PipamperoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pomalidomide.
PosaconazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Posaconazole.
PramipexoleZuclopenthixol may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Zuclopenthixol.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Zuclopenthixol.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Zuclopenthixol.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Zuclopenthixol.
PrimidoneThe serum concentration of Zuclopenthixol can be decreased when it is combined with Primidone.
PrimidoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Primidone.
ProcainamideProcainamide may increase the QTc-prolonging activities of Zuclopenthixol.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Zuclopenthixol.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Zuclopenthixol.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zuclopenthixol.
PromazinePromazine may increase the QTc-prolonging activities of Zuclopenthixol.
PromazineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Zuclopenthixol.
PropafenonePropafenone may increase the QTc-prolonging activities of Zuclopenthixol.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Zuclopenthixol.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Zuclopenthixol.
PropoxycaineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Zuclopenthixol.
PSD502The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Zuclopenthixol.
QuetiapineQuetiapine may increase the QTc-prolonging activities of Zuclopenthixol.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Zuclopenthixol.
QuinidineQuinidine may increase the QTc-prolonging activities of Zuclopenthixol.
QuinineQuinine may increase the QTc-prolonging activities of Zuclopenthixol.
RamelteonThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ramelteon.
RanolazineThe serum concentration of Zuclopenthixol can be increased when it is combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Zuclopenthixol.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Zuclopenthixol.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Zuclopenthixol.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Zuclopenthixol.
RifabutinThe serum concentration of Zuclopenthixol can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Zuclopenthixol can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Zuclopenthixol can be decreased when it is combined with Rifapentine.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Zuclopenthixol.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Zuclopenthixol.
RitonavirThe serum concentration of Zuclopenthixol can be increased when it is combined with Ritonavir.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Zuclopenthixol.
RolapitantThe metabolism of Zuclopenthixol can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Romifidine.
RopiniroleZuclopenthixol may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Zuclopenthixol can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Zuclopenthixol.
RotigotineZuclopenthixol may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Zuclopenthixol.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with S-Ethylisothiourea.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Zuclopenthixol.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Zuclopenthixol.
SaquinavirSaquinavir may increase the QTc-prolonging activities of Zuclopenthixol.
ScopolamineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Zuclopenthixol.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Zuclopenthixol.
SertindoleThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Zuclopenthixol.
SildenafilThe serum concentration of Zuclopenthixol can be increased when it is combined with Sildenafil.
Sodium oxybateThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Sodium oxybate.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Zuclopenthixol.
SorafenibSorafenib may increase the QTc-prolonging activities of Zuclopenthixol.
SotalolSotalol may increase the QTc-prolonging activities of Zuclopenthixol.
StiripentolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Zuclopenthixol.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Zuclopenthixol.
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Zuclopenthixol.
SulpirideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Zuclopenthixol.
SunitinibSunitinib may increase the QTc-prolonging activities of Zuclopenthixol.
SuvorexantThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Suvorexant.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Zuclopenthixol.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Zuclopenthixol.
TasimelteonThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tasimelteon.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Zuclopenthixol.
TelaprevirThe serum concentration of Zuclopenthixol can be increased when it is combined with Telaprevir.
TelavancinTelavancin may increase the QTc-prolonging activities of Zuclopenthixol.
TelithromycinTelithromycin may increase the QTc-prolonging activities of Zuclopenthixol.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Zuclopenthixol.
TerbinafineThe metabolism of Zuclopenthixol can be decreased when combined with Terbinafine.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Zuclopenthixol.
TetrabenazineZuclopenthixol may increase the QTc-prolonging activities of Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tetrodotoxin.
ThalidomideZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Zuclopenthixol.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Zuclopenthixol.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Zuclopenthixol.
ThioridazineThioridazine may increase the QTc-prolonging activities of Zuclopenthixol.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Zuclopenthixol.
TiagabineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tiagabine.
TiclopidineThe serum concentration of Zuclopenthixol can be increased when it is combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tiletamine.
TipranavirThe metabolism of Zuclopenthixol can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tolcapone.
TolterodineTolterodine may increase the QTc-prolonging activities of Zuclopenthixol.
TopiramateThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Topiramate.
ToremifeneToremifene may increase the QTc-prolonging activities of Zuclopenthixol.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Zuclopenthixol.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Zuclopenthixol.
TrazodoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Trazodone.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Zuclopenthixol.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Zuclopenthixol.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zuclopenthixol.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Zuclopenthixol.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Zuclopenthixol.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Zuclopenthixol.
TriprolidineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Triprolidine.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Zuclopenthixol.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Zuclopenthixol.
VandetanibZuclopenthixol may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Zuclopenthixol.
VemurafenibZuclopenthixol may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe serum concentration of Zuclopenthixol can be increased when it is combined with Venlafaxine.
VerapamilThe serum concentration of Zuclopenthixol can be increased when it is combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Vigabatrin.
VilanterolVilanterol may increase the QTc-prolonging activities of Zuclopenthixol.
VilazodoneThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Vilazodone.
VoriconazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Voriconazole.
VorinostatVorinostat may increase the QTc-prolonging activities of Zuclopenthixol.
VortioxetineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Zuclopenthixol.
ZiconotideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Zimelidine.
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Zuclopenthixol.
ZolazepamThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Zuclopenthixol.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Zuclopenthixol.
ZonisamideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Zuclopenthixol.
ZotepineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Zotepine.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Lublin H, Gerlach J, Hagert U, Meidahl B, Molbjerg C, Pedersen V, Rendtorff C, Tolvanen E: Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. Eur Neuropsychopharmacol. 1991 Dec;1(4):541-8. [PubMed:1822319 ]
  2. Manzaneque JM, Navarro JF: An ethopharmacological assessment of the effects of zuclopenthixol on agonistic interactions in male mice. Methods Find Exp Clin Pharmacol. 1999 Jan-Feb;21(1):11-5. [PubMed:10222441 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD5
Uniprot ID:
P21918
Molecular Weight:
52950.5 Da
References
  1. Lublin H, Gerlach J, Hagert U, Meidahl B, Molbjerg C, Pedersen V, Rendtorff C, Tolvanen E: Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. Eur Neuropsychopharmacol. 1991 Dec;1(4):541-8. [PubMed:1822319 ]
  2. Manzaneque JM, Navarro JF: An ethopharmacological assessment of the effects of zuclopenthixol on agonistic interactions in male mice. Methods Find Exp Clin Pharmacol. 1999 Jan-Feb;21(1):11-5. [PubMed:10222441 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Gareri P, De Fazio P, Stilo M, Ferreri G, De Sarro G: Conventional and atypical antipsychotics in the elderly : a review. Clin Drug Investig. 2003;23(5):287-322. [PubMed:17535043 ]
  2. Lublin H, Gerlach J, Hagert U, Meidahl B, Molbjerg C, Pedersen V, Rendtorff C, Tolvanen E: Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. Eur Neuropsychopharmacol. 1991 Dec;1(4):541-8. [PubMed:1822319 ]
  3. Nyberg S, Farde L, Bartfai A, Halldin C: Central D2 receptor occupancy and effects of zuclopenthixol acetate in humans. Int Clin Psychopharmacol. 1995 Nov;10(4):221-7. [PubMed:8748043 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Khalifa AE: Zuclopenthixol facilitates memory retrieval in rats: possible involvement of noradrenergic and serotonergic mechanisms. Pharmacol Biochem Behav. 2003 Jul;75(4):755-62. [PubMed:12957216 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Khalifa AE: Zuclopenthixol facilitates memory retrieval in rats: possible involvement of noradrenergic and serotonergic mechanisms. Pharmacol Biochem Behav. 2003 Jul;75(4):755-62. [PubMed:12957216 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Nyberg S, Farde L, Bartfai A, Halldin C: Central D2 receptor occupancy and effects of zuclopenthixol acetate in humans. Int Clin Psychopharmacol. 1995 Nov;10(4):221-7. [PubMed:8748043 ]
  2. Gjerden P, Slordal L, Bramness JG: Association between the use of anticholinergic antiparkinson drugs and safety and receptor drug-binding profiles of antipsychotic agents. Eur J Clin Pharmacol. 2009 Dec;65(12):1229-35. doi: 10.1007/s00228-009-0696-6. [PubMed:19644682 ]
  3. Khalifa AE: Zuclopenthixol facilitates memory retrieval in rats: possible involvement of noradrenergic and serotonergic mechanisms. Pharmacol Biochem Behav. 2003 Jul;75(4):755-62. [PubMed:12957216 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Link [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Comments
comments powered by Disqus
Drug created on August 29, 2007 14:18 / Updated on August 17, 2016 12:23